NCT01379963

Brief Summary

This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
780

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2009

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 30, 2009

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 22, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 23, 2011

Completed
4.5 years until next milestone

Results Posted

Study results publicly available

December 24, 2015

Completed
Last Updated

July 13, 2017

Status Verified

May 1, 2017

Enrollment Period

1.8 years

First QC Date

June 22, 2011

Results QC Date

November 20, 2015

Last Update Submit

June 15, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of Participants Who Achieved a 3-month Hemoglobin Level Stabilization in the Range of 11-12 Grams Per Deciliter (g/dL)

    Hemoglobin level stabilization within the range of 11-12 g/dL was measured on a monthly basis according to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, for enrolled participants who had received methoxy-polyethylene-glycol-epoetin beta treatment.

    Up to 6 months

Secondary Outcomes (1)

  • Percentage of Participants Who Achieved a 6-month Hemoglobin Level Stabilization in the Range of 11-12 g/dL

    Up to 6 months

Study Arms (1)

Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with renal anemia on treatment with Mircera

You may qualify if:

  • Adult patients, \>/= 18 years of age
  • Renal anemia treated with Mircera for at least 6 months before entering study

You may not qualify if:

  • Patients who refuse or are incapable of giving their written informed consent to retrospective data collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Timios Stavros Clinic; Nephrology Department

Aigáleo, 12244, Greece

Location

General Hospital of Artas; Nephrology

Arta, 47100, Greece

Location

Pantokrator Private Clinic; Nephrology

Athens, 10433, Greece

Location

Attikon Center; Nephrology

Athens, 11362, Greece

Location

Athinaiki Private Clinic

Athens, 11521, Greece

Location

Kyanos Stavros Private Hospital; Nephrologic Clinic

Athens, 11528, Greece

Location

Iaso General Private Clinic; Nephrology

Athens, 15562, Greece

Location

Iatriko Athinon Clinic Dafnis; Nephrology Department

Daphni-athens, 17237, Greece

Location

Kyanous Stavros of Patras, Renal Disease Therapy Unit

Pátrai, 26225, Greece

Location

Olympion Therapeytirion; Nefrology

Pátrai, 26443, Greece

Location

Iasis Private Clinic

Piraeus, 42356, Greece

Location

General Hospital Of Chalkidikis; Dialysis Center Unit

Polygyros, 63100, Greece

Location

Diavalkaniko Kentro; Nephrology

Thessaloniki, 57001, Greece

Location

General Hospital of Thessalonikis G.Papanikolaou; Nephrology

Thessaloniki, 57010, Greece

Location

Alfa Nefrodynamiki; Nefrology

Thessaloniki, 57500, Greece

Location

Thessaliki Nossileytiki; Nephrology

Volos, 38221, Greece

Location

General Hospital of Volos; Nephrology

Volos, 38222, Greece

Location

MeSH Terms

Conditions

AnemiaKidney DiseasesBronchiolitis Obliterans Syndrome

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesOrganizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesGraft vs Host DiseaseImmune System Diseases

Results Point of Contact

Title
Medical Communications
Organization
Hoffmann-LaRoche

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 22, 2011

First Posted

June 23, 2011

Study Start

April 30, 2009

Primary Completion

February 28, 2011

Study Completion

February 28, 2011

Last Updated

July 13, 2017

Results First Posted

December 24, 2015

Record last verified: 2017-05

Locations